EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Acute GIP and GLP ‐1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals

Liva S L Krogh iD, Maja B Hansen, Natasha C Bergmann, Carsten P Hansen, Bolette Hartmann, Jens J Holst iD, Filip K Knop, Asger B Lund, Lærke S Gasbjerg iD

Diabetes, Obesity and Metabolism · 2026-08 · 28 (8) · 7280-7290

DOI: 10.1111/dom.70940 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 01.06.2026. Verfasst von Liva S L Krogh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. Hauptthemen laut MEDLINE: Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Incretins, Pancreatectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Foundation for the Study of Diabetes, Aase og Ejnar Danielsens Fond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

While being recognised for stimulating pancreatic insulin secretion, GIP and GLP‐1 exert various extrapancreatic effects relevant in the context of incretin‐based therapies. Here, we evaluated the extrapancreatic effects of GIP and GLP‐1, separately and combined, on postprandial physiology in totally pancreatectomised individuals. Materials and Methods In a randomised double‐blind design, 12 totally pancreatectomised individuals (five women, age: [mean ± SD] 58.8 ± 13.9 years; BMI: 24.7 ± 5.1 kg/m 2 ) each underwent four liquid mixed meal tests (480 kcal) during 270‐min intravenous infusions of GIP (4 pmol/kg/min), GLP‐1 (1 pmol/kg/min), GIP+GLP‐1 and saline (placebo), respectively. Blood samples, appetite‐related measures, hemodynamic measures, and ad libitum food intake data were collected. Participants continued basal insulin but omitted other medications including bolus insulin from 10 p.m. the night before.

Results

Compared to placebo, GLP‐1 infusion reduced postprandial glucose excursions by 45% ± 48% ( p = 0.005) and gastric emptying rate by 29% ± 36%, assessed by acetaminophen absorption ( p = 0.05), whereas the effects of GIP were similar to placebo. During GIP+GLP‐1 co‐infusion, ad libitum food intake was 31% ± 22% lower compared to placebo ( p = 0.018) but similar to GLP‐1 infusion. Compared to placebo, infusion of GIP increased heart rate by 10 ± 5.9 bpm ( p = 0.004), decreased diastolic blood pressure by 9.1 ± 5.4 bpm ( p = 0.002), and inhibited postprandial bone resorption assessed by carboxy‐terminal collagen crosslinks by 65% ± 35% ( p = 0.003), whereas GLP‐1 infusion did not affect bone resorption markers.

Conclusion

Physiological actions of GIP and GLP‐1 were preserved in totally pancreatectomised individuals, demonstrating independency of endogenous pancreatic factors. Trial Registration: ClinicalTrials.gov : NCT06895408

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastric Inhibitory PolypeptideGlucagon-Like Peptide 1IncretinsPancreatectomyAgedFemaleHumansMaleMiddle AgedBlood GlucoseDouble-Blind MethodGastric EmptyingInfusions, IntravenousInsulinPancreasPostprandial Period

Stichwörter der Autor:innen

glucagon‐like peptide 1glucose‐dependent insulinotropic polypeptideincretin hormonespancreatogenic diabetestotal pancreatectomy

Substanzen

Blood GlucoseGastric Inhibitory PolypeptideGlucagon-Like Peptide 1IncretinsInsulin

Autor:innen und Institutionen

  • Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • Department of Surgery and Transplantation, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
  • Novo Nordisk A/S, Bagsværd, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Liva S L Krogh, Jens J Holst, Lærke S Gasbjerg

Förderung

  • European Foundation for the Study of Diabetes
  • Aase og Ejnar Danielsens Fond

Zitieren

APA

Krogh, L. S. L., Hansen, M. B., Bergmann, N. C., Hansen, C. P., Hartmann, B., Holst, J. J., Knop, F. K., Lund, A. B., & Gasbjerg, L. S. (2026). Acute GIP and GLP ‐1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals. Diabetes, Obesity and Metabolism, 28(8), 7280-7290. https://doi.org/10.1111/dom.70940

Vancouver

Krogh LSL, Hansen MB, Bergmann NC, Hansen CP, Hartmann B, Holst JJ, et al. Acute GIP and GLP ‐1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals. Diabetes, Obesity and Metabolism. 2026;28(8):7280-7290. doi:10.1111/dom.70940

BibTeX
@article{Krogh2026,
  author = {Krogh, Liva S L and Hansen, Maja B and Bergmann, Natasha C and Hansen, Carsten P and Hartmann, Bolette and Holst, Jens J and Knop, Filip K and Lund, Asger B and Gasbjerg, Lærke S},
  title = {Acute GIP and GLP ‐1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {8},
  pages = {7280--7290},
  doi = {10.1111/dom.70940}
}
Kostenlos starten →